Drugs / WX-081
WX-081
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06701110 | Sep 2024 → Dec 2025 overdue | tuberculosis | Shanghai Jiatan Pharmatech Co., Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04608955 | Oct 2020 → Apr 2022 | pulmonary tuberculosis | Shanghai Jiatan Pharmatech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WX-081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06701110 ↗ |
| Known as | 21l | “Based on bedaquiline, we describe herein discovery and development of a novel diarylpyridine series, which led to identification of WX-081 (sudapyridine, 21l).” PMID 35636648 ↗ May 2022 |
| Known as | sudapyridine | “Based on bedaquiline, we describe herein discovery and development of a novel diarylpyridine series, which led to identification of WX-081 (sudapyridine, 21l).” PMID 35636648 ↗ May 2022 |
| Modality | Small molecule | “Based on bedaquiline, we describe herein discovery and development of a novel diarylpyridine series, which led to identification of WX-081 (sudapyridine, 21l).” PMID 35636648 ↗ May 2022 |
| Route | Oral | “Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.” NCT04608955 ↗ |